Fortunately, the paper shows that this particular treatment doesn't attack normal cells, but it may cause trouble longer term (which is one reason additional sa

Fortunately, the paper shows that this particular treatment doesn't attack normal cells, but it may cause trouble longer term (which is one reason additional safety studies are required before human trials). Also, I'm pretty sure there is already an increase in autoimmune disorders after current immuno-oncology (IO) treatment. Patients should certainly have that information before treatment.